查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829859

2025年子宫颈癌诊断全球市场报告

Cervical Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，子宫颈癌诊断市场规模强劲成长，从2024年的92.7亿美元增加至2025年的97.6亿美元，复合年增长率为5.3%。预测期内的成长可归因于认知度的提高、筛检计画的推进、HPV疫苗接种、技术进步以及人口老化。

子宫颈癌诊断市场预计将在未来几年强劲成长，到2029年将达到122.9亿美元，复合年增长率为5.9%。预测期内的成长归因于HPV相关癌症的增加、新兴市场、分子检测、远端医疗和远距筛检的进步。预测期内的主要趋势包括HPV检测、液基细胞学、自动化和数位病理学以及筛检和治疗方案。

子宫颈癌是一种发生于子宫颈（子宫下部）的鳞状细胞癌。子宫颈癌诊断设备用于检测影响子宫颈的癌症。

子宫颈癌诊断的主要类型包括乳头抹片检查、HPV检测、阴道镜检查、切片检查、子宫颈管刮除术和其他诊断方法。乳头抹片检查是一种用于检测女性子宫颈癌的方法。此诊断过程涵盖21岁以下、21至29岁、30至65岁以及65岁以上的年龄层。这些检测的最终用户包括医院、专科诊所、癌症和放射治疗中心以及诊断中心等。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要重新认证医疗设备，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供子宫颈癌诊断市场统计数据，包括全球子宫颈癌诊断行业市场规模、区域份额、子宫颈癌诊断市场份额竞争对手、详细的子宫颈癌诊断细分市场、市场趋势和商业机会，以及您在子宫颈癌诊断行业取得成功所需的数据。本子宫颈癌诊断市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的全方位观点。

我们预测未来五年该市场将成长5.9%，较我们先前对该市场的预测略有下降0.2%。下降主要源自于美国与其他国家之间关税的影响。这可能会透过对来自义大利和韩国等主要地区的液基乳头瘤病毒 (HPV)去氧核糖核酸(DNA)杂合反应探针征收套件直接影响美国，从而可能降低筛检能力并增加早期癌症检测的成本。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，这种影响可能会更加广泛。

子宫颈癌诊断检测在早期发现的应用日益广泛，预计将推动子宫颈癌诊断市场的成长。女性对子宫颈癌认识的不断提高，以及全球癌症组织和各国政府对早期发现和预防检测的日益重视，都促进了市场的扩张。例如，美国政府机构疾病管制与预防中心 (CDC) 在 2024 年 7 月报告称，2021 年美国新增子宫颈癌病例 12,536 例，2022 年有 4,051 名女性死于子宫颈癌。子宫颈癌诊断检测的广泛应用和对早期发现的重视是推动子宫颈癌诊断市场成长的关键因素。

子宫颈癌盛行率的上升预计将成为子宫颈癌诊断市场成长的主要驱动力。子宫颈癌发生在子宫颈（子宫下部较窄的部分），是一个严重的健康问题。子宫颈癌诊断检测在早期发现、准确诊断和有效治疗中发挥着至关重要的作用。例如，根据美国临床肿瘤学会 (ASCO) 患者资讯网站 Cancer.net 的估计，美国约有 13,960 名女性将被诊断出患有侵袭性子宫颈癌。因此，子宫颈癌发生率的上升预计将支持子宫颈癌诊断市场的成长。

为了提高筛检的可近性并提高早期发现率，子宫颈癌诊断市场的主要企业正致力于开发技术先进的解决方案，例如HPV自采集。 HPV自采集可让个人独立采集检体进行人类乳突病毒（HPV）检测，HPV是子宫颈癌的主要原因。例如，2024年5月，瑞士製药公司F. Hoffmann-La Roche AG的HPV自采集解决方案获得FDA核准。这项技术创新标誌着子宫颈癌筛检领域的一个重要里程碑，提高了筛检的可近性，特别是对于服务不足的人。此解决方案可让女性私下采集阴道样本，并使用罗氏的cobas分子HPV检测试剂盒进行检测，这与世界卫生组织（WHO）在2030年消除子宫颈癌的目标一致。 FDA的核准是在IMPACT试验成功完成之后进行的，该试验检验了该解决方案在不同人群中的有效性。

子宫颈癌诊断行业的主要企业正在优先开发先进的数位诊断系统，以提高筛检的可及性和早期发现率。数位诊断系统利用人工智慧 (AI) 和数位工具等最尖端科技来支援子宫颈癌的检测、诊断和管理。例如，2024 年 2 月，美国医疗技术公司 Hologic 的 Genius 数位诊断系统获得了 FDA 批准。这项突破性的解决方案将 Genius Cervical AI 演算法与先进的体积成像技术相结合，显着提高了癌前病变和子宫颈癌细胞的检测率。与传统方法相比，它将假阴性减少了 28%，从而改善了早期发现和患者预后。透过数位化细胞学切片并利用人工智慧指导细胞学家和病理学家识别需要进一步分析的区域，它优化了工作流程效率并促进了医疗专业人员之间的远端协作。

2022年2月，医疗设备和试剂製造商BD（Becton, Dickinson & Company）收购了Cytognos，收购金额未揭露。 BD收购Cytognos加强了对慢性病管理的承诺，并扩展了其诊断产品组合、免疫评估测试和资讯学，以深入了解免疫系统、免疫反应和微小残留疾病（MRD）。 Cytognos总部位于西班牙，专门提供用于子宫颈癌诊断的临床流式细胞技术解决方案。

子宫颈癌诊断市场的主要企业包括雅培实验室 (Abbott Laboratories)、碧迪公司 (Becton Dickinson and Company, BD)、Bio-Rad Laboratories Inc.、F. Hoffmann-La Roche Ltd.、Hologic Inc.、QIAGEN NV、Quest Diagicotics Incorporated、西门子医疗股份公司 Ltd. Inc.、Guided Therapeutics Inc.、赛默飞世尔科技 (Thermo Fisher Scientific Inc.)、卡尔蔡司股份公司 (Carl Zeiss AG)、OncoHealth Corporation、Arbor Vita Corporation、Micromedic Technologies Ltd.、Trovagene Inc.、罗氏诊断 (Roche Diagnostics)、Nucleix Ltd.、华大基因 Ltd. Inc.、Invitae Corporation、Natera Inc.、NeoGenomics Laboratories Inc.、珀金埃尔默公司 (PerkinElmer Inc.)、Sysmex Corporation、Veracyte Inc. 和 Zymo Research Corporation。

2024年，北美是子宫颈癌诊断市场最大的地区。亚太地区是子宫颈癌诊断市场的第二大地区。子宫颈癌诊断市场报告涵盖亚太地区、西欧、东欧、北美、南美以及中东和非洲。

子宫颈癌诊断市场报告涵盖的国家包括澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国、美国、义大利、西班牙和加拿大

子宫颈癌诊断市场涵盖用于诊断子宫颈癌的分析仪、试剂和其他产品的销售。市场价值包括服务供应商销售或包含在其服务产品中的相关商品的价值。仅包括企业之间交易或销售给最终消费者的商品和服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球子宫颈癌诊断：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球子宫颈癌诊断市场：成长率分析
  • 全球子宫颈癌诊断市场表现：规模与成长，2019-2024
  • 全球子宫颈癌诊断市场预测：规模与成长，2024-2029年，2034年
  • 全球子宫颈癌诊断：总目标市场（TAM）

第六章 市场细分

  • 全球子宫颈癌诊断市场（按诊断测试、效能和预测），2019-2024 年、2024-2029 年、2034 年
  • 子宫颈抹片抹片检查
  • HPV检测
  • 阴道镜检查
  • 切片检查和子宫颈刮除术
  • 其他诊断测试
  • 全球子宫颈癌诊断市场依年龄层、绩效及预测（2019-2024 年、2024-2029 年、2034 年）
  • 未满21岁
  • 21至29岁
  • 30至65岁
  • 65岁或以上
  • 全球子宫颈癌诊断市场（按最终用户、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 专科诊所
  • 癌症及放射治疗中心
  • 诊断中心
  • 全球子宫颈癌诊断市场：子宫颈抹片检查细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 传统子宫颈抹片抹片检查
  • 液态子宫颈抹片
  • 全球子宫颈癌诊断市场：按 HPV 检测类型、效能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 基于DNA的HPV检测
  • 基于RNA的HPV检测
  • 杂交捕获HPV检测
  • 其他 HPV 检测
  • 全球子宫颈癌诊断市场：阴道镜细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 标准阴道镜检查
  • 电子阴道镜检查
  • 光学阴道镜检查
  • 全球子宫颈癌诊断市场：切片检查及子宫颈刮除细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 穿刺切片检查
  • 子宫颈刮除术（ECC）
  • 切除术
  • 阴道镜切片检查
  • 全球子宫颈癌诊断市场：依其他诊断检验细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 使用醋酸进行目视检查（VIA）
  • 子宫颈巴氏试验
  • 血液检查
  • 其他专业测试

第七章 区域和国家分析

  • 全球子宫颈癌诊断市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球子宫颈癌诊断市场：依国家、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 子宫颈癌诊断市场：竞争格局
  • 子宫颈癌诊断市场：公司简介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Becton Dickinson and Company（BD）Overview, Products and Services, Strategy and Financial Analysis
    • Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Zilico Ltd.
  • Guided Therapeutics Inc.
  • Thermo Fisher Scientific Inc.
  • Carl Zeiss AG
  • OncoHealth Corporation
  • Arbor Vita Corporation
  • Micromedic Technologies Ltd.
  • Trovagene Inc.
  • Roche Diagnostics
  • Nucleix Ltd.
  • BGI Genomics Co. Ltd.
  • Cepheid

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年子宫颈癌诊断市场：提供新机会的国家
  • 2029年子宫颈癌诊断市场：细分市场带来新机会
  • 子宫颈癌诊断市场2029年：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r32448u

Cervical cancer is a form of squamous cell carcinoma that develops in the cervix, which is the lower part of the uterus. Diagnostic devices for cervical cancer are employed to detect cancer affecting the cervix.

The primary types of cervical cancer diagnostics include pap smear tests, HPV tests, colposcopy, biopsy, endocervical curettage, and other diagnostic procedures. A pap smear test is a method used for the detection of cervical cancer in women. This diagnostic process encompasses age groups such as those under 21, those aged 21 to 29, those aged 30 to 65, and those over 65. These diagnostics are utilized by various end-users, including hospitals, specialty clinics, cancer and radiation therapy centers, as well as diagnostic centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The cervical cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cervical cancer diagnostics market statistics, including cervical cancer diagnostics industry global market size, regional shares, competitors with a cervical cancer diagnostics market share, detailed cervical cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer diagnostics industry. This cervical cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cervical cancer diagnostics market size has grown strongly in recent years. It will grow from $9.27 billion in 2024 to $9.76 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased awareness and screening programs, hpv vaccination, technological advancements, aging population.

The cervical cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $12.29 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing hpv-related cancers, emerging markets, molecular testing advances, telemedicine and remote screening. Major trends in the forecast period include hpv testing, liquid-based cytology, automation and digital pathology, screen-and-treat programs.

The forecast of 5.9% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on liquid-based cytology collection kits and human papillomavirus (HPV) deoxyribonucleic acid (DNA) hybridization probes, sourced from key regions such as Italy and South Korea, which could lead to reduced screening capacity and higher costs for early cancer detection.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing adoption of cervical cancer diagnostic tests for early detection is expected to drive the growth of the cervical cancer diagnostics market. Rising awareness among women about cervical cancer, along with global cancer organizations and governments' emphasis on early testing for detection and prevention, contributes to the market's expansion. For example, in July 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported 12,536 new cases of cervical cancer in the United States in 2021, while in 2022, the disease led to 4,051 fatalities among women. The growing adoption of cervical cancer diagnostic tests and the focus on early diagnosis are key factors driving the growth of the cervical cancer diagnostics market.

The increasing prevalence of cervical cancer is anticipated to be a key driver of growth in the cervical cancer diagnostics market. Cervical cancer, originating in the cervix, the narrow lower portion of the uterus, is a serious health concern. Diagnostic tests for cervical cancer play a pivotal role in early detection, accurate diagnosis, and effective treatment. For instance, estimates from Cancer.net, the patient information website of the American Society of Clinical Oncology (ASCO), suggest that approximately 13,960 women in the United States will be diagnosed with invasive cervical cancer. Consequently, the rising incidence of cervical cancer is expected to underpin the growth of the cervical cancer diagnostics market.

Leading companies in the cervical cancer diagnostics market are emphasizing the development of technologically advanced solutions, such as HPV self-collection methods, to enhance screening accessibility and improve early detection rates. HPV self-collection solutions enable individuals to independently collect samples for testing the human papillomavirus (HPV), a primary cause of cervical cancer. For instance, in May 2024, F. Hoffmann-La Roche AG, a pharmaceutical company based in Switzerland, secured FDA approval for its HPV self-collection solution. This innovation marks a significant milestone in cervical cancer screening by improving accessibility, particularly for underserved populations. The solution allows women to privately collect vaginal samples for testing using Roche's Cobas molecular HPV test, aligning with the World Health Organization's objective of eradicating cervical cancer by 2030. The FDA approval follows the successful IMPACT trial, which validated the solution's effectiveness across various demographic groups.

Prominent players in the cervical cancer diagnostics industry are prioritizing the development of advanced digital diagnostic systems to enhance screening accessibility and early detection capabilities. Digital diagnostic systems leverage cutting-edge technologies, including artificial intelligence (AI) and digital tools, to support the detection, diagnosis, and management of cervical cancer. For example, in February 2024, Hologic, Inc., a US-based health technology firm, obtained FDA clearance for its Genius Digital Diagnostics System. This groundbreaking solution integrates the Genius Cervical AI algorithm with advanced volumetric imaging technology to significantly improve the detection of precancerous lesions and cervical cancer cells. By reducing false negatives by 28% compared to traditional methods, the system enhances early detection and patient outcomes. It digitizes cytology slides and employs AI to guide cytologists and pathologists in identifying areas needing further analysis, thereby optimizing workflow efficiency and facilitating remote collaboration among healthcare professionals.

In February 2022, BD (Becton, Dickinson, and Company), a manufacturer of medical devices and reagents, acquired Cytognos for an undisclosed amount. BD's acquisition of Cytognos strengthens its commitment to chronic disease management, expanding its diagnostic portfolio, immune assessment tests, and informatics to gain deeper insights into the immune system, immune response, and Minimal Residual Disease (MRD). Cytognos, a Spain-based company, specializes in providing clinical flow cytometry solutions used in cervical cancer diagnostics.

Major companies operating in the cervical cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Zilico Ltd., Guided Therapeutics Inc., Thermo Fisher Scientific Inc., Carl Zeiss AG, OncoHealth Corporation, Arbor Vita Corporation, Micromedic Technologies Ltd., Trovagene Inc., Roche Diagnostics, Nucleix Ltd., BGI Genomics Co. Ltd., Cepheid, Exact Sciences Corporation, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., PerkinElmer Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation

North America was the largest region in the cervical cancer diagnostics market in 2024 Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cervical cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The cervical cancer diagnostics market consists of sales of analyzer, reagents, and others that are used for the diagnosis of cervical cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cervical Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cervical cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cervical cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cervical cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Diagnostic Test: Pap Smear Test; HPV Test; Colposcopy; Biopsy and Endocervical Curettage; Other Diagnostic Tests
  • 2) By Age Group: Below 21; Age between 21 to 29; Age between 30 to 65; Above 65
  • 3) By End User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Diagnostic Centers
  • Subsegments:
  • 1) By Pap Smear Test: Conventional Pap Smear; Liquid-Based Pap Smear
  • 2) By HPV Test: DNA-Based HPV Test; RNA-Based HPV Test; Hybrid Capture HPV Test; Other HPV Tests
  • 3) By Colposcopy: Standard Colposcopy; Digital Colposcopy; Optical Colposcopy
  • 4) By Biopsy And Endocervical Curettage: Punch Biopsy; Endocervical Curettage (ECC); Cone Biopsy; Colposcopic Biopsy
  • 5) By Other Diagnostic Tests: Visual Inspection With Acetic Acid (VIA); Cervical Cytology Testing; Blood Tests; Other Specialty Tests
  • Companies Mentioned: Abbott Laboratories; Becton Dickinson and Company (BD); Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Hologic Inc.; QIAGEN N.V.; Quest Diagnostics Incorporated; Siemens Healthineers AG; Zilico Ltd.; Guided Therapeutics Inc.; Thermo Fisher Scientific Inc.; Carl Zeiss AG; OncoHealth Corporation; Arbor Vita Corporation; Micromedic Technologies Ltd.; Trovagene Inc.; Roche Diagnostics; Nucleix Ltd.; BGI Genomics Co. Ltd.; Cepheid; Exact Sciences Corporation; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; PerkinElmer Inc.; Sysmex Corporation; Veracyte Inc.; Zymo Research Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cervical Cancer Diagnostics Market Characteristics

3. Cervical Cancer Diagnostics Market Trends And Strategies

4. Cervical Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cervical Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cervical Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cervical Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Cervical Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cervical Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cervical Cancer Diagnostics Total Addressable Market (TAM)

6. Cervical Cancer Diagnostics Market Segmentation

  • 6.1. Global Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pap Smear Test
  • HPV Test
  • Colposcopy
  • Biopsy and Endocervical Curettage
  • Other Diagnostic Tests
  • 6.2. Global Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Below 21
  • Age between 21 to 29
  • Age between 30 to 65
  • Above 65
  • 6.3. Global Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Cancer and Radiation Therapy Centers
  • Diagnostic Centers
  • 6.4. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Pap Smear Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Conventional Pap Smear
  • Liquid-Based Pap Smear
  • 6.5. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of HPV Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-Based HPV Test
  • RNA-Based HPV Test
  • Hybrid Capture HPV Test
  • Other HPV Tests
  • 6.6. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Colposcopy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Standard Colposcopy
  • Digital Colposcopy
  • Optical Colposcopy
  • 6.7. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Biopsy And Endocervical Curettage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Punch Biopsy
  • Endocervical Curettage (ECC)
  • Cone Biopsy
  • Colposcopic Biopsy
  • 6.8. Global Cervical Cancer Diagnostics Market, Sub-Segmentation Of Other Diagnostic Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Visual Inspection With Acetic Acid (VIA)
  • Cervical Cytology Testing
  • Blood Tests
  • Other Specialty Tests

7. Cervical Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Cervical Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cervical Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cervical Cancer Diagnostics Market

  • 8.1. Asia-Pacific Cervical Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cervical Cancer Diagnostics Market

  • 9.1. China Cervical Cancer Diagnostics Market Overview
  • 9.2. China Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cervical Cancer Diagnostics Market

  • 10.1. India Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cervical Cancer Diagnostics Market

  • 11.1. Japan Cervical Cancer Diagnostics Market Overview
  • 11.2. Japan Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cervical Cancer Diagnostics Market

  • 12.1. Australia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cervical Cancer Diagnostics Market

  • 13.1. Indonesia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cervical Cancer Diagnostics Market

  • 14.1. South Korea Cervical Cancer Diagnostics Market Overview
  • 14.2. South Korea Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cervical Cancer Diagnostics Market

  • 15.1. Western Europe Cervical Cancer Diagnostics Market Overview
  • 15.2. Western Europe Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cervical Cancer Diagnostics Market

  • 16.1. UK Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cervical Cancer Diagnostics Market

  • 17.1. Germany Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cervical Cancer Diagnostics Market

  • 18.1. France Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cervical Cancer Diagnostics Market

  • 19.1. Italy Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cervical Cancer Diagnostics Market

  • 20.1. Spain Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cervical Cancer Diagnostics Market

  • 21.1. Eastern Europe Cervical Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cervical Cancer Diagnostics Market

  • 22.1. Russia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cervical Cancer Diagnostics Market

  • 23.1. North America Cervical Cancer Diagnostics Market Overview
  • 23.2. North America Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cervical Cancer Diagnostics Market

  • 24.1. USA Cervical Cancer Diagnostics Market Overview
  • 24.2. USA Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cervical Cancer Diagnostics Market

  • 25.1. Canada Cervical Cancer Diagnostics Market Overview
  • 25.2. Canada Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cervical Cancer Diagnostics Market

  • 26.1. South America Cervical Cancer Diagnostics Market Overview
  • 26.2. South America Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cervical Cancer Diagnostics Market

  • 27.1. Brazil Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cervical Cancer Diagnostics Market

  • 28.1. Middle East Cervical Cancer Diagnostics Market Overview
  • 28.2. Middle East Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cervical Cancer Diagnostics Market

  • 29.1. Africa Cervical Cancer Diagnostics Market Overview
  • 29.2. Africa Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cervical Cancer Diagnostics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cervical Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Cervical Cancer Diagnostics Market Competitive Landscape
  • 30.2. Cervical Cancer Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Becton Dickinson and Company (BD) Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Cervical Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. QIAGEN N.V.
  • 31.2. Quest Diagnostics Incorporated
  • 31.3. Siemens Healthineers AG
  • 31.4. Zilico Ltd.
  • 31.5. Guided Therapeutics Inc.
  • 31.6. Thermo Fisher Scientific Inc.
  • 31.7. Carl Zeiss AG
  • 31.8. OncoHealth Corporation
  • 31.9. Arbor Vita Corporation
  • 31.10. Micromedic Technologies Ltd.
  • 31.11. Trovagene Inc.
  • 31.12. Roche Diagnostics
  • 31.13. Nucleix Ltd.
  • 31.14. BGI Genomics Co. Ltd.
  • 31.15. Cepheid

32. Global Cervical Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cervical Cancer Diagnostics Market

34. Recent Developments In The Cervical Cancer Diagnostics Market

35. Cervical Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Cervical Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cervical Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cervical Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer